Get Involved


Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare, debilitating disease affecting children and young adults. Dynacure’s Dyn101 development program is based on the modulation of the expression of the Dynamin 2 protein, through the use of an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals, the leading biopharmaceutical company in RNA-targeted drug discovery.



Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’

Read a letter to patients and families about upcoming clinical trials

  1. English Translation
  2. Spanish Translation
  3. French Translation
  4. Dutch Translation
  5. Italian Translation
  6. German Translation
  7. Danish Translation


An Intergrated Modelling Methodology for Estimating the Prevalence of Centronuclear Myopathy 

Dynacure Secures $55 Million Financing to Advance Lead Program into Clinical Development